Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

770 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Determining the PASS cut-off points for the FIQR, FASmod and PSD in patients with fibromyalgia: a registry-based study.
Salaffi F, Di Carlo M, Di Franco M, Bianchi G, Bazzichi L, Tirri R, Guiducci S, Gorla R, Atzeni F, Giacomelli R, Di Donato E, Guggino G, Fischetti F, Tirri E, Biasi G, Foti R, Dagna L, Carubbi F, Gremese E, Govoni M, Cutolo M, Iannone F, Lippolis I, Conti F, Tramontano G, Marino V, Farah S, Sarzi-Puttini P; Società Italiana di Reumatologia (SIR). Salaffi F, et al. Among authors: cutolo m. Clin Exp Rheumatol. 2023 Jun;41(6):1275-1282. doi: 10.55563/clinexprheumatol/on8j9a. Epub 2023 May 3. Clin Exp Rheumatol. 2023. PMID: 37140611 Free article.
Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
Iannone F, Trotta F, Montecucco C, Giacomelli R, Galeazzi M, Matucci-Cerinic M, Ferri C, Cutolo M, Maria Bambara L, Triolo G, Ferraccioli G, Valentini G, Lapadula G; GISEA (Gruppo Italiano per lo Studio delle Early Arthritis). Iannone F, et al. Among authors: cutolo m. Ann Rheum Dis. 2007 Feb;66(2):249-52. doi: 10.1136/ard.2006.058776. Epub 2006 Jul 12. Ann Rheum Dis. 2007. PMID: 16837489 Free PMC article.
Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, Malesci D, Massara A, Nacci F, Secchi ME, Manganelli S, Salaffi F, Bambara ML, Bombardieri S, Cutolo M, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Grassi W, Lapadula G, Cerinic MM, Montecucco C, Trotta F, Triolo G, Valentini G, Valesini G, Ferraccioli GF; GISEA group. Mancarella L, et al. Among authors: cutolo m. J Rheumatol. 2007 Aug;34(8):1670-3. Epub 2007 Jul 1. J Rheumatol. 2007. PMID: 17611987
Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
Quartuccio L, Fabris M, Salvin S, Atzeni F, Saracco M, Benucci M, Cimmino M, Morassi P, Masolini P, Pellerito R, Cutolo M, Puttini PS, De Vita S. Quartuccio L, et al. Among authors: cutolo m. Rheumatology (Oxford). 2009 Dec;48(12):1557-9. doi: 10.1093/rheumatology/kep314. Epub 2009 Sep 29. Rheumatology (Oxford). 2009. PMID: 19789202
770 results